Business Context and Reporting Period
Company: Artiva Biotherapeutics, Inc. (Nasdaq: ARTV)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2025
Business Overview: Artiva is a clinical-stage biotechnology company developing allogeneic, "off-the-shelf" natural killer (NK) cell-based therapies for autoimmune diseases and cancers. The company's lead product candidate, AlloNK (AB-101), is a non-genetically modified NK cell therapy evaluated in combination with B-cell targeted monoclonal antibodies (mAbs). The company operates as a single reportable segment focused on the development of these therapies.
Key Financial Metrics
| Metric | 2025 (in millions) | 2024 (in millions) |
|---|---|---|
| Revenue | $0.0 | $0.3 |
| Net Loss | $(83.9) | $(65.4) |
| Research & Development Expenses | $69.5 | $50.3 |
| General & Administrative Expenses | $20.3 | $17.2 |
| Cash, Cash Equivalents & Investments | $108.0 | $185.4 |
| Accumulated Deficit | $(330.5) | $(246.7) |
| Net Cash Used in Operating Activities | $(76.8) | $(55.0) |
Note: The filing text does not provide specific gross margin or operating margin percentages as the company has no product revenue.
Material Changes vs. Prior Period
- Increased Net Loss: Net loss increased by $18.5 million (28%) from 2024 to 2025, driven primarily by higher operating expenses.
- R&D Expense Growth: R&D expenses increased by $19.2 million (38%), primarily due to a $12.1 million increase in external costs for AlloNK clinical trials and a $7.1 million increase in internal personnel costs.
- Revenue Decline: Revenue dropped to zero in 2025 from $0.3 million in 2024. The 2024 revenue was related to development support activities under an amended license agreement with GC Cell, which did not recur in 2025.
- Cash Position: Cash, cash equivalents, and investments decreased by approximately $77.4 million, reflecting the burn rate from operations and investment maturities.
Guidance, Outlook, and Management Commentary
Clinical Progress & Outlook:
- AlloNK (AB-101): The company is prioritizing refractory Rheumatoid Arthritis (RA) as the lead indication. In November 2025, data from 32 patients showed consistent and complete B-cell depletion by Day 13. The company plans to share initial clinical response data from over 15 refractory RA patients in the first half of 2026.
- Regulatory Milestones: AlloNK received FDA Fast Track Designation for refractory RA (October 2025) and Lupus Nephritis (February 2024). The company plans FDA regulatory interactions in H1 2026 to align on pivotal trial design.
- Manufacturing: Artiva operates a 9,000 sq. ft. cGMP manufacturing center in San Diego. Commercial Cost of Goods Sold (COGS) is estimated between $3,000 and $12,000 per patient, significantly lower than autologous CAR-T therapies.
Liquidity & Capital Needs:
- As of December 31, 2025, the company held $108.0 million in cash and investments.
- Management estimates current funds are sufficient to fund operations into the second quarter of 2027.
- The company expects to continue incurring significant losses and will require additional funding to complete clinical development and commercialization.
Risks & Contingencies:
- Collaboration Termination: The collaboration with Affimed GmbH was terminated in July 2025 following Affimed's insolvency filing.
- Regulatory Uncertainty: No cell therapy is currently approved for autoimmune diseases; regulatory pathways are evolving.
- Capital Risk: Failure to raise additional capital could force delays or reductions in R&D programs.
Key Facts for Investor Verification
- Cash Runway: Verify the sufficiency of the $108.0 million cash balance to fund operations through Q2 2027, considering potential acceleration of clinical trials.
- Clinical Data Readouts: Monitor the release of clinical response data for refractory RA patients expected in the first half of 2026.
- Manufacturing Scalability: Assess the capacity and cost-efficiency of the San Diego cGMP facility relative to projected commercial demand.
- Regulatory Interactions: Track the outcome of planned FDA meetings in H1 2026 regarding pivotal trial design for RA.
- Collaboration Dependencies: Review the status of the GC Cell license agreements and the impact of the terminated Affimed collaboration on the pipeline.